Unveiling Other Side of coin: linking SGLT2 Inhibitors to Euglycemic Diabetic Ketoacidosis
India: In a startling revelation, a recent case study has brought to light an uncommon yet potentially life-threatening complication associated with Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, raising concerns within the medical community. The study emphasizes the importance of vigilance in monitoring patients receiving these medications.
SGLT2 inhibitors, hailed for their efficacy in managing type 2 diabetes by promoting urinary glucose excretion, have gained widespread acceptance in clinical practice. However, emerging evidence suggests a rare but severe adverse effect – euglycemic diabetic ketoacidosis (EDKA), characterized by ketoacidosis with blood glucose levels within the normal or mildly elevated range. With their increasing use in the management of type 2 diabetes mellitus due to long-term beneficial effects, there is a rise in the incidence of this complication.
The recent case, published in Cureus, signifies the importance of awareness of the link between the SGLT2 inhibitors use and EDKA and early recognition of this complication to reduce mortality and morbidity. Furthermore, it also emphasizes the need for clinicians to educate their patients taking these drugs to prevent them during the intercurrent illness to prevent them from developing EDKA.
Sangita D. Kamath, Internal Medicine, Tata Main Hospital, Jamshedpur, IND, and colleagues report the case of a 58-year-old lady with a history of type 2 diabetes mellitus (T2DM) on multiple anti-diabetes medications, including dapagliflozin for one year, who during intercurrent illness developed EDKA.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.